Market cap
₹6 Cr
Revenue (TTM)
₹72 Cr
P/E Ratio
214.8
P/B Ratio
1.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 22.85 | -79.38 | 9.11 | 32.70 | 48.48 |
| EBIT | 377.65 | -60.86 | 236.47 | -57.06 | -5.14 |
| Net Profit | -6.85 | -75.89 | 109.57 | -70.35 | -45.75 |
| EPS | -7.36 | -75.84 | 108.77 | -71.09 | -46.63 |
| Book Value | -- | -- | 9.95 | 2.13 | 6.65 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| -2.20 | 0.52 | 0.16 | 0.62 | -4.97 |
| Net Margin
| -6.94 | -0.09 | 0.04 | 0.34 | -9.01 |
| Return on equity
| -0.01 | 6.43 | 0.64 | 9.48 | -15.67 |
| Return on Capital
| 4.16 | 7.32 | -- | 6.09 | -2.74 |
| Return on Assets
| -0.16 | 1.36 | 0.07 | 2.05 | -3.75 |
| Debt to Equity (x)
| -- | -- | 0.60 | 2.34 | 2.18 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
--
|
6.09
|
-2.74
|
10.18
|
10.83
|
|
Peer Median
|
--
|
26.16
|
3.84
|
5.02
|
--
|
ROE
0.64
Lower than Peers by 4.18
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
0.64
|
9.48
|
-15.67
|
12.54
|
15.78
|
|
Peer Median
|
4.82
|
23.64
|
5.08
|
1.59
|
--
|
ROA
0.07
Lower than Peers by 4.37
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
0.07
|
2.05
|
-3.75
|
2.61
|
3.15
|
|
Peer Median
|
4.44
|
15.65
|
2.19
|
1.46
|
--
|
EBIT Margin
0.16
Higher than Peers by 3.04
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
0.16
|
0.62
|
-4.97
|
3.81
|
3.74
|
|
Peer Median
|
-2.88
|
--
|
2.93
|
3.78
|
--
|
Net Margin
0.04
Lower than Peers by 2.18
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
0.04
|
0.34
|
-9.01
|
1.96
|
3.27
|
|
Peer Median
|
2.22
|
10.82
|
1.96
|
3.27
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
--
|
0.36
|
-8.89
|
2.01
|
3.37
|
|
Peer Median
|
--
|
--
|
0.00
|
0.00
|
--
|
Revenue Growth
9.11
Lower than Peers by 18.45
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
9.11
|
1,461.44
|
-73.33
|
56.31
|
71.22
|
|
Peer Median
|
27.56
|
--
|
50.75
|
56.32
|
--
|
EBIT Growth
236.47
Higher than Peers by 200.57
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
236.47
|
293.80
|
-134.83
|
59.02
|
1,175.00
|
|
Peer Median
|
35.90
|
--
|
75.04
|
59.55
|
--
|
Net Profit Growth
109.57
Higher than Peers by 49.02
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
109.57
|
158.51
|
-223.17
|
-8.52
|
79.67
|
|
Peer Median
|
60.55
|
--
|
39.96
|
-8.68
|
--
|
EPS Growth
108.77
Higher than Peers by 84.21
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
108.77
|
158.52
|
-223.17
|
-8.56
|
79.59
|
|
Peer Median
|
24.56
|
--
|
-21.00
|
--
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
--
|
9.95
|
-14.53
|
13.38
|
17.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.60
Higher than Peers by 0.60
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
0.60
|
2.34
|
2.18
|
1.11
|
1.95
|
|
Peer Median
|
0.00
|
0.49
|
--
|
0.63
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
--
|
2.14
|
1.34
|
0.54
|
1.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.24
Lower than Peers by 1.22
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
1.24
|
1.13
|
1.35
|
1.29
|
1.15
|
|
Peer Median
|
2.46
|
2.50
|
2.47
|
2.33
|
--
|
Quick Ratio
1.08
Lower than Peers by 0.79
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
1.08
|
0.92
|
1.11
|
1.13
|
1.01
|
|
Peer Median
|
1.86
|
--
|
1.68
|
10.32
|
--
|
Interest Coverage
1.80
Lower than Peers by 2.51
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
1.80
|
2.92
|
-0.86
|
2.66
|
2.68
|
|
Peer Median
|
4.32
|
6.09
|
2.66
|
2.65
|
--
|
Operating Efficiency
Debtors to sales
27.61
Higher than Peers by 5.61
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
27.61
|
10.68
|
108.57
|
41.46
|
70.08
|
|
Peer Median
|
22.00
|
--
|
15.37
|
42.99
|
--
|
Asset Turnover
1.84
Higher than Peers by 0.64
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
1.84
|
6.02
|
0.41
|
1.33
|
0.94
|
|
Peer Median
|
1.20
|
--
|
1.51
|
1.33
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
--
|
32.19
|
481.83
|
157.48
|
208.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
--
|
9.15
|
104.96
|
29.38
|
50.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
--
|
15.65
|
290.39
|
125.07
|
166.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
--
|
25.69
|
296.40
|
61.79
|
92.27
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
214.81
Higher than Peers by 148.69
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
214.81
|
17.85
|
--
|
49.63
|
125.69
|
|
Peer Median
|
66.12
|
13.12
|
65.30
|
159.13
|
--
|
Price / Book Value
1.29
Lower than Peers by 3.90
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
1.29
|
1.62
|
2.01
|
5.86
|
18.38
|
|
Peer Median
|
5.18
|
2.40
|
2.35
|
3.26
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
27.31
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
27.31
|
20.23
|
-56.16
|
28.56
|
72.57
|
|
Peer Median
|
--
|
10.38
|
53.35
|
29.43
|
--
|
Market Cap
6
Lower than Peers by 9,208
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Vivanza Bioscience
|
6
|
7
|
8
|
27
|
75
|
|
Peer Median
|
9,214
|
144
|
30
|
20
|
--
|